Are you Dr. Piperdi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 57 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Lake Ave N
Department Of Hematology/Oncology
Worcester, MA 01655Phone+1 508-856-3933- Is this information wrong?
Summary
- Dr. Bilal Piperdi, MD is an oncologist in Worcester, Massachusetts. He is currently licensed to practice medicine in Massachusetts and New York. He is affiliated with Montefiore Medical Center and is an Assistant Professor at University Massachusetts Medical School.
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2001 - 2004
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1998 - 2001
Hacettepe University FOMClass of 1997
Certifications & Licensure
NY State Medical License 2011 - 2024
MA State Medical License 2004 - 2012
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
- A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . . Start of enrollment: 2010 May 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsAssociations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.Marina C Garassino, Shirish Gadgeel, Silvia Novello, Balazs Halmos, Enriqueta Felip, Giovanna Speranza, Rina Hui, Edward B Garon, Hidehito Horinouchi, Shunichi Sugawar...> ;JTO Clinical and Research Reports. 2023 Jan 1
- 3 citationsIndirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi> ;Immunotherapy. 2022 Apr 1
- 33 citationsOutcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and ...Aaron S. Mansfield, Roy S. Herbst, Gilberto de Castro, Rina Hui, Nir Peled, Dong Wan Kim, Silvia Novello, Miyako Satouchi, Yi-Long Wu, Edward B. Garon, Martin Reck, An...> ;JTO Clinical and Research Reports. 2021 Aug 1
- Join now to see all
Press Mentions
An Expert Take on Lung CancerNovember 26th, 2019
Professional Memberships
- Member
Hospital Affiliations
Montefiore Medical CenterBronx, New York
